Brain:百健(Biogen)突破性进展被梅奥诊所新研究泼冷水

2015-03-24 佚名 生物谷

上周五,百健(Biogen)公布了其实验性阿尔茨海默氏症(AD)药物BIIB037激动人心的早期数据。然而,本周来自梅奥诊所(Mayo Clinic)的一项最新研究,却给百健的突破性进展迎头泼了一盆冷水,该研究可能会重新掀起有关制药行业在研AD药物是否真的找到了正确靶标的长期争论。本周二发表于神经学期刊《大脑》(Brain)上的最新研究中,来自梅奥诊所的研究人员发现,tau蛋白的异常积累是阿尔茨海

上周五,百健(Biogen)公布了其实验性阿尔茨海默氏症(AD)药物BIIB037激动人心的早期数据。然而,本周来自梅奥诊所(Mayo Clinic)的一项最新研究,却给百健的突破性进展迎头泼了一盆冷水,该研究可能会重新掀起有关制药行业在研AD药物是否真的找到了正确靶标的长期争论。

本周二发表于神经学期刊《大脑》(Brain)上的最新研究中,来自梅奥诊所的研究人员发现,tau蛋白的异常积累是阿尔茨海默氏症(AD)患者认知衰退和记忆丧失的真正源头。研究人员发现,tau蛋白破坏了整个大脑中细胞用于运输食物和信息的通道。而百健艾迪的药物BIIN037及其他几个处于后期研发阶段的药物,则靶向的是另一种蛋白——β淀粉样蛋白(β-amyloid)。

梅奥诊所神经科学家Melissa Murray在接受电话采访时表示,β淀粉样蛋白与认知功能衰退有关,但如果将它和tau放在一起看,tau才是坏分子。而在过去的25年间,关于阿尔茨海默氏症(AD)的大多数研究都集中于β淀粉样蛋白。

在该项最新研究中,研究人员调查了超过3600例死于不同阶段老年痴呆症的患者的大脑,其中近1400例患者确诊阿尔茨海默氏症(AD)。通过检测疾病进展各个阶段大脑中的β淀粉样蛋白和tau蛋白,研究人员得出结论,tau蛋白水平能够预测患者认知恶化的速度。

Murray指出,当异常tau蛋白在大脑记忆中心——海马(hippocampus)中积累时,认知能力通常开始下降。最终,有毒的tau蛋白会在大脑皮层(cortex)中聚集,而这部分大脑参与了更高层次的思考、规划、行为及注意力。

目前,包括强生(JNJ)、百健(Biogen)、艾伯维(AbbVie)在内的多家制药公司,有一些处于早期阶段的产品靶向tau蛋白。另一家制药公司TauRx Pharmaceuticals目前正在更广泛的临床试验中调查另一种tau靶向药物。

阿尔茨海默氏症(AD)协会科学倡议理事Dean Harley表示,梅奥诊所的研究并没有降低β淀粉样蛋白可能参与阿尔茨海默氏症(AD)疾病进展的思想高度。这些结果可能表明,科学家需要考虑多种方法和多个靶标。这取决于患者所处的疾病阶段,可能需要特定类型的治疗药物。如果处于疾病晚期,可能tau蛋白是及其重要的,但如果我们不希望有任何临床症状出现,那么我们要做的可能是靶向β淀粉样蛋白。

百健(Biogen)的突破性数据:

上周五,百健发布了实验性阿尔茨海默氏症(AD)药物BIIB037一项Ib期临床研究结果,数据显示BIIB037明显逆转了β淀粉样蛋白在大脑中的聚集,并且在降低认知能力下降方面也表现出积极的迹象。消息发布后该公司股价飙升10%。有分析师预计,如果BIIB037在III期临床获得成功并上市,该药将成为百健和合作伙伴日本卫材(Eisai)年销超100亿美元的重磅产品。

不过,这只是处于临床开发的一个β淀粉样蛋白靶向药物。礼来目前也在调查另一种单抗solanezumab用于较早阶段的患者。而罗氏,尽管在去年12月因糟糕数据终止了一种β淀粉样蛋白靶向药物在早期阶段AD患者的研究,但仍正继续推进该药用于轻度痴呆症的AD患者。(原题:Brain最新研究再掀tau-β淀粉蛋白之争,百健(Biogen)突破性进展被泼冷水!)

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1662517, encodeId=a71c166251e2a, content=<a href='/topic/show?id=2a8be18387e' target=_blank style='color:#2F92EE;'>#百健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71838, encryptionId=2a8be18387e, topicName=百健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26925418654, createdName=yuhaisheng_ibp_32061719, createdTime=Tue May 05 05:22:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917141, encodeId=8e8d191e1416d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 19 19:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310940, encodeId=f4ec1310940da, content=<a href='/topic/show?id=39be91564e5' target=_blank style='color:#2F92EE;'>#诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91564, encryptionId=39be91564e5, topicName=诊所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368245, encodeId=844e1368245b4, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404329, encodeId=be33140432942, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489717, encodeId=12501489e1723, content=<a href='/topic/show?id=39dd6242530' target=_blank style='color:#2F92EE;'>#梅奥诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62425, encryptionId=39dd6242530, topicName=梅奥诊所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22488584370, createdName=echonoir, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1662517, encodeId=a71c166251e2a, content=<a href='/topic/show?id=2a8be18387e' target=_blank style='color:#2F92EE;'>#百健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71838, encryptionId=2a8be18387e, topicName=百健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26925418654, createdName=yuhaisheng_ibp_32061719, createdTime=Tue May 05 05:22:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917141, encodeId=8e8d191e1416d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 19 19:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310940, encodeId=f4ec1310940da, content=<a href='/topic/show?id=39be91564e5' target=_blank style='color:#2F92EE;'>#诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91564, encryptionId=39be91564e5, topicName=诊所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368245, encodeId=844e1368245b4, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404329, encodeId=be33140432942, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489717, encodeId=12501489e1723, content=<a href='/topic/show?id=39dd6242530' target=_blank style='color:#2F92EE;'>#梅奥诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62425, encryptionId=39dd6242530, topicName=梅奥诊所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22488584370, createdName=echonoir, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
    2016-01-19 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1662517, encodeId=a71c166251e2a, content=<a href='/topic/show?id=2a8be18387e' target=_blank style='color:#2F92EE;'>#百健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71838, encryptionId=2a8be18387e, topicName=百健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26925418654, createdName=yuhaisheng_ibp_32061719, createdTime=Tue May 05 05:22:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917141, encodeId=8e8d191e1416d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 19 19:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310940, encodeId=f4ec1310940da, content=<a href='/topic/show?id=39be91564e5' target=_blank style='color:#2F92EE;'>#诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91564, encryptionId=39be91564e5, topicName=诊所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368245, encodeId=844e1368245b4, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404329, encodeId=be33140432942, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489717, encodeId=12501489e1723, content=<a href='/topic/show?id=39dd6242530' target=_blank style='color:#2F92EE;'>#梅奥诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62425, encryptionId=39dd6242530, topicName=梅奥诊所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22488584370, createdName=echonoir, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
    2015-03-26 ycmayy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1662517, encodeId=a71c166251e2a, content=<a href='/topic/show?id=2a8be18387e' target=_blank style='color:#2F92EE;'>#百健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71838, encryptionId=2a8be18387e, topicName=百健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26925418654, createdName=yuhaisheng_ibp_32061719, createdTime=Tue May 05 05:22:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917141, encodeId=8e8d191e1416d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 19 19:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310940, encodeId=f4ec1310940da, content=<a href='/topic/show?id=39be91564e5' target=_blank style='color:#2F92EE;'>#诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91564, encryptionId=39be91564e5, topicName=诊所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368245, encodeId=844e1368245b4, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404329, encodeId=be33140432942, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489717, encodeId=12501489e1723, content=<a href='/topic/show?id=39dd6242530' target=_blank style='color:#2F92EE;'>#梅奥诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62425, encryptionId=39dd6242530, topicName=梅奥诊所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22488584370, createdName=echonoir, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1662517, encodeId=a71c166251e2a, content=<a href='/topic/show?id=2a8be18387e' target=_blank style='color:#2F92EE;'>#百健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71838, encryptionId=2a8be18387e, topicName=百健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26925418654, createdName=yuhaisheng_ibp_32061719, createdTime=Tue May 05 05:22:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917141, encodeId=8e8d191e1416d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 19 19:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310940, encodeId=f4ec1310940da, content=<a href='/topic/show?id=39be91564e5' target=_blank style='color:#2F92EE;'>#诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91564, encryptionId=39be91564e5, topicName=诊所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368245, encodeId=844e1368245b4, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404329, encodeId=be33140432942, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489717, encodeId=12501489e1723, content=<a href='/topic/show?id=39dd6242530' target=_blank style='color:#2F92EE;'>#梅奥诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62425, encryptionId=39dd6242530, topicName=梅奥诊所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22488584370, createdName=echonoir, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]
    2015-03-26 qjddjq
  6. [GetPortalCommentsPageByObjectIdResponse(id=1662517, encodeId=a71c166251e2a, content=<a href='/topic/show?id=2a8be18387e' target=_blank style='color:#2F92EE;'>#百健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71838, encryptionId=2a8be18387e, topicName=百健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26925418654, createdName=yuhaisheng_ibp_32061719, createdTime=Tue May 05 05:22:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917141, encodeId=8e8d191e1416d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 19 19:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310940, encodeId=f4ec1310940da, content=<a href='/topic/show?id=39be91564e5' target=_blank style='color:#2F92EE;'>#诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91564, encryptionId=39be91564e5, topicName=诊所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368245, encodeId=844e1368245b4, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404329, encodeId=be33140432942, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489717, encodeId=12501489e1723, content=<a href='/topic/show?id=39dd6242530' target=_blank style='color:#2F92EE;'>#梅奥诊所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62425, encryptionId=39dd6242530, topicName=梅奥诊所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22488584370, createdName=echonoir, createdTime=Thu Mar 26 08:22:00 CST 2015, time=2015-03-26, status=1, ipAttribution=)]

相关资讯

美医学博士称流感疫苗或会损伤大脑

外媒称,美国著名全科家庭医生戴维·布朗斯坦博士表示,尽管流感疫苗被宣传为安全无害,但情况并非如此。流感疫苗含有几种可疑成分,包括致癌物甲醛,而且多种流感疫苗含有以硫柳汞形式存在的汞。 据美国健康医疗指南网站11月20日报道,布朗斯坦博士告诉网站:“汞是人类已知的毒性最大的物质之一。它是一种强力神经毒素,与神经系统和免疫系统的很多问题都有关联。千万不能把汞注入活人体内。” 美国国家卫

JAMA Neurol:伴癫痫发作的阿尔茨海默症患者更早出现轻度认知功能障碍

根据JAMA Neurology的一篇报道,对于存在遗忘型轻度认知功能损害(aMCI)或阿尔茨海默病(AD)的患者,伴有癫痫发作者出现认知功能减退要早于无癫痫者。根据研究背景可知,AD可增加患者的癫痫发作风险。与无癫痫的AD患者相比,伴有癫痫的AD患者其认知损害更显著,症状进展更快,且尸检发现其神经元缺失更严重。加利福尼亚州旧金山市格莱斯顿神经疾病研究所的Keith A(医学博士,理学硕士)及其同

CHM :DNA甲基化暴露疟原虫致命弱点

说到疟疾大多数人想到的只是蚊子,其实疟原虫才是罪魁祸首,蚊子只是携带者。2010年,全球有两亿多人受到疟原虫的感染,其中约六十六万人死亡。更令人头疼的是,这种寄生虫对青蒿素也显示出了抗性,青蒿素曾是治疗感染者的最有效药物。 现在,加州大学的研究人员发现了疟原虫的潜在弱点。研究显示,基因组中的低水平DNA甲基化,对于寄生虫的生存非常关键。文章发表在Cell旗下的Cell Host

Crenezumab还有希望造福阿尔茨海默症患者吗?

罗氏(Roche)旗下基因泰克(Genentech)昨天发布了在研药物crenezumab的一个II期研究结果。这个药物旨在通过阻断一种名为β-淀粉样蛋白的累积,从而达到延缓阿尔茨海默症的效果。 罗氏(Roche)旗下基因泰克(Genentech)昨天发布了在研药物crenezumab的一个II期研究结果。这个药物旨在通过阻断一种名为β-淀粉样蛋白的累积,从而达到延缓阿尔茨海默症的效果。

Science:六篇论文结论相互矛盾 阿尔茨海默氏病特效药争议悬而未决

2012年《科学》(Science)杂志曾发表研究指出,癌症药物 Bexarotene 可以用来治疗阿尔茨海默症,但近日有科学家对此发出了质疑。四个独立研究小组在本期《Science》杂志上报告,他们未能完全重复 Bexarotene 的惊人效果。 2012年3月,Gary Landreth 等人发表的研究称,癌症药物 Bexarotene 可以降低大脑中的β淀粉样蛋白浓度,甚至逆转阿尔茨海默症

JAD:坚持母乳喂养可降低母亲罹患阿尔茨海默症风险

日前,英国剑桥大学的一项最新研究发现,母乳喂养不仅对婴儿的健康成长有利,对母亲来说也有好处,那些在抚育孩子期间坚持母乳喂养的女性晚年罹患阿尔茨海默症(也称为老年性痴呆)的风险比那些没有进行母乳喂养的女性会更小,且坚持母乳喂养的时间越长,这种风险就越低。 这一研究成果发表在最新一期《阿尔茨海默症杂志》上,是研究人员通过对81名年龄介于70岁至100岁之间的英国妇女进行调查研究后得出。 研究人员搜